Table 1 Demographic and clinical characteristics of confirmed infections by rapid antigen testing
Individual No. | Vaccine type for booster | Age | Sex | Date of symptom onset | Interval days between vaccination and infectiona | Symptoms |
|---|---|---|---|---|---|---|
A005 | Trivalent XBB.1.5 vaccine | 69 | Male | 10/15/2024 | 170 | Cough |
A030 | Trivalent XBB.1.5 vaccine | 71 | Male | 8/17/2024 | 111 | Sore throat, nasal congestion, and dizziness |
B031 | Bivalent Omicron XBB vaccine | 67 | Male | 7/28/2024 | 91 | Fatigue |
B036 | Bivalent Omicron XBB vaccine | 70 | Female | 6/10/2024 | 43 | Cough |
B037 | Bivalent Omicron XBB vaccine | 66 | Female | 6/19/2024 | 52 | Sore throat and runny nose |
B044 | Bivalent Omicron XBB vaccine | 66 | Female | 8/22/2024 | 116 | Cough and sore throat |
B059 | Bivalent Omicron XBB vaccine | 66 | Female | 7/22/2024 | 85 | Cough, fatigue, and nasal congestion |
B060 | Bivalent Omicron XBB vaccine | 68 | Female | 6/15/2024 | 48 | Sore throat and nasal congestion |
C061 | Tetravalent XBB.1 vaccine | 74 | Male | 7/1/2024 | 64 | Cough, sore throat, fatigue, and nasal congestion |
C064 | Tetravalent XBB.1 vaccine | 68 | Male | 10/18/2024 | 173 | Cough, headache, and runny nose |
C071 | Tetravalent XBB.1 vaccine | 72 | Female | 10/10/2024 | 165 | Cough |
